Síndrome de miembros inferiores post trasplante / Post-transplant distal limb syndrome

El síndrome de miembros inferiores post trasplante (SMIPT) es una entidad poco conocida con una prevalencia del 5% en pacientes con trasplante renal. Su diagnóstico se basa en la clínica, afectando predominantemente miembros inferiores de forma simétrica y bilateral, centellograma óseo y resonancia magnética nuclear (RMN). Tiene una evolución benigna y se cura sin secuelas. Presentamos el caso de un hombre de 37 años con antecedentes de enfermedad de Berger en 1999 que requirió diálisis trisemanal por 4 años (2009-2013) y posterior trasplante renal en julio del 2013. Consultó en enero del 2014 refiriendo dolor intenso en ambos pies, de inicio súbito, recordando la fecha exacta del inicio del dolor, sin relación con traumatismo, que impedía su deambulación. En el centellograma óseo se observó fijación patológica del radiotrazador en pies sin diferencia de captación entre ambos. Si bien aún no hay tratamiento específico, la evolución de esta enfermedad es benigna.

The post-transplant distal limb syndrome is a not well known entity, with a prevalence of 5% in patients with renal transplant. Its diagnosis is based on clinical symptoms, bone scintigraphy and MRI, it has a benign course and the patient recovers without sequel. We present the case of a 37-year-old male, with medical history of hypertension, Berger's disease in 1999 that required dialysis three times a week for four years (2009-2013) and renal transplant in 2013. The patient consults on January 2014 referring severe pain in both feet, with sudden onset; he remembers the exact date of the beginning of the pain and denies trauma, pain prevents ambulation. The bone scintigraphy shows pathological uptake in both feet with no difference between the two. Although there is no treatment for this disease, it has a benign course.

The clinical efficacy and safety of tacrolimus in patients with myasthenia gravis / 中华内科杂志

Objective To evaluate the efficacy and safety of tacrolimus in patients with generalized myasthenia gravis (MG).Methods A total of 69 cases admitted to our hospital were given 2-6 mg/day tacrolimus (FK506) for 12 months.The MG absolute and relative clinical scores were used to monitor the efficacy of tacrolimus.Clinical evaluation was conducted at month 1,3,6,and 12,while the serum concentration of FK506 was measured at one month after administration of tacromus for one month.Results The therapeutic response presenting as improved muscular strength showed within one month after administration of tacrolimus.The overall response rates (MG relative clinical score≥25％) at month 1,3,6 were 81.2％,87.6％,92.2％ respectively.It reached 93.8％ by the final visit at month 12.MG score to evaluate disease severity decreased significantly as the subjects continued to take tacrolimus.Statistic analysis suggested that the serum concentration of FK506 was correlated with its therapeutic effect.Serum trough levels in remission and response groups [(7.1 ± 3.9) μg/L and (6.3 ± 3.8) pg/L,respectively] were significantly higher than that of no response group [(3.4 ± 1.3) μg/L].The most common adverse effects included hyperglycemia (5 cases),myelosuppression (3 cases),and dizziness tinnitus (3 cases),majority of which were temporary and manageable.Conclusions Our study has shown that tacrolimus significantly improved muscular strength of generalized MG patients.The treatment is well tolerated.The therapeutic effect of tacrolimus is observed within 1 month after initial use.Adverse events were manageable and not common.

A Case of Zosteriform Kaposi's Sarcoma after Prednisolon Treatment / 대한피부과학회지

Kaposi's sarcoma is a rare lympho-angioproliferative neoplasm with four types of variants: classic, iatrogenic immunosuppressive drug-associated, AIDS-related and Africa-endemic Kaposi's sarcoma. Most immunosuppressive drug- associated Kaposi's sarcomas usually occur after a kidney transplant or after receiving immunosuppressive therapy. A 64-year-old female patient showed numerous purpuric nodules and smaller erythematous plaques on the right lower leg for three months. Previously, the patient was treated with an immunosuppressive drug for rapidly progressive glomerulonephritis for a five-week period. A skin biopsy was performed under the clinical diagnosis of Kaposi's sarcoma. We performed immunohistochemical staining and polymerase chain reaction to detect human herpes virus 8 (HHV-8). We report a case of iatrogenic immunosuppressive drug-associated zosteriform Kaposi's sarcoma that rapidly occurred five weeks after prednisolon therapy in a rapidly progressive glomerulonephritis patient.

The Case Report of Burn Wound Healing in the Patient with Arteriovenous Fistula

PURPOSE: Arteriovenous fistula (AV fistula) and immune suppressive drug have a different effect on wound healing. AV fistula supposed to have a positive role of wound healing by the increased blood flow around the wound. But immunosuppressive drug has a well known effect of delayed wound healing. METHODS: We experienced 55 years old female patient who suffered from 9% burn of TBSA, 2nd to 3rd degree burn of arm and chest wall with arteriovenous fistula in the burned arm. She also take immunosuppressive drugs for 13 years due to kidney transplantation. RESULTS: She takes two consecutive skin graft operations on post admission day 14 and 42. Bleeding from the surface of eschar excised arm was profuse so it makes us unable to finish in the first operation. But graft skins were well taken except partial take-off in chest wall area. Episode of shock make 2nd skin graft postponed for a month but the skin uptake of arm was very successful. CONCLUSION: The arteriovenous fistula has the positive effect in the case of burn wound healing including the skin graft, exceed the negative role of immunosuppressive drugs in the wound healing.

Immunosuppressive Effects of Tautomycetin on T Cells / 대한면역학회지

T cell activation is a critical event for initiation and regulation of immune responses and inhibitors of such signaling pathways are clinically useful for the treatment of patients received allogratt and autoimmune disease. In the course of screening soil microorganisms from the forest of Cheju island in Korea for new immunosuppressive agent, one of Streptomyces species (CK-95441) was found to produce a new immunosuppressant, tautomycetin which also had antifungal activity. Tautomycetin showed the inhibition of T cell proliferation in murine mixed lymphocyte reaction (MLR) and T cell activation induced by concanavalin A. Tautomycetin also blocked the induction of IL-2 gene expression which was examined in Jurkat TAg cell line in which multiple NFAT-binding sites and minimal IL-2 promoter drive the production of B-galactosidase. Also, the level of inhibition in activation-induced IL-2 receptor expression by tautomycetin was greater than those by cyclosporin A measured by flow cytometry. But, Fas ligand-induced apoptosis in Jurkat cells was unaffected by tautomycetin which was measured by DNA fragmentation assay. These results suggested that tautomycetin will be able to be used as a potent immunosuppressive drug following organ transplantation.

Okadaic Acid, RK682 and Calyculin Modulate TcR - Mediated Signaling Events / 대한면역학회지

The T cell antigen receptor (TcR) in combination with costimulatory signals triggered by accessory molecules present on the surface of the antigen-presenting cells (APC) regulates the activation and growth of T lymphocytes. Calyculin A and Okadaic acid is known to be an inhibitor of serine/threonine phosphatase and RK-682 specifically blocks functions of tyrosine phosphatase. To investigate roles of these inhibitors in TcR-mediated signaling cascade, chimeric molecule CD8-5 which contains the extracellular and transmembrane domains of the human CD8a molecule and the cytoplasmic tail of TcR 5 chain were stably expressed in Jurkat cell line. CD8-5 chimeric protein induced tyrosine phosphorylation of various cytoplasmic substrates and IL-2 gene expression in a NFAT dependent manner by stimulation with anti-CD8 mAb OKT8 as seen in TcR stimulation. When CD8-5 transfectants were preincubated with Okadaic acid, Calyculin or RK682, they differentially affected tyrosine phosphorylation of signaling mediators including CD8-5 molecule. When Jurkat Tag cell line was used where SV40 T antigen is stably expressed and the expression of p-galactosidase is driven by the multiple NFAT binding sites plus minimal IL-2 promoter, these phosphatase inhibitors -RK682, Calyculin A, Okadaic acid- effectively inhibited IL-2 gene expression at the concentration of 1.2832 x 10 ' M, 3.9924 x 10 M, 7.2707 x 10 M respectively. These results suggested that Okadaic acid, Calyculin or RK682 modulate TcR-proximal as well as TcR-distal signaling events during T cell activation.